<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164163</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL1011</org_study_id>
    <secondary_id>COG-ADVL1011</secondary_id>
    <nct_id>NCT01164163</nct_id>
  </id_info>
  <brief_title>INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease</brief_title>
  <official_title>A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of&#xD;
      the enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424&#xD;
      in treating young patients with relapsed or refractory solid tumor, leukemia, or&#xD;
      myeloproliferative disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To estimate the maximum-tolerated dose and/or recommended phase II dose of oral JAK&#xD;
           inhibitor INCB18424 administered continuously, twice daily to pediatric patients with&#xD;
           relapsed or refractory solid tumors.&#xD;
&#xD;
        -  To define and describe the toxicities of this treatment administered on this schedule in&#xD;
           pediatric patients with relapsed or refractory solid tumors, leukemias, or&#xD;
           myeloproliferative neoplasms (MPNs).&#xD;
&#xD;
        -  To characterize the pharmacokinetics of this treatment in pediatric patients with&#xD;
           relapsed or refractory solid tumors, leukemias, or MPNs.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To preliminarily define the antitumor activity of this treatment within the confines of&#xD;
           a phase I study.&#xD;
&#xD;
        -  To assess the biologic activity of oral JAK inhibitor INCB18424 upon JAK-STAT signaling&#xD;
           in pediatric patients with relapsed or refractory solid tumors, leukemias, or MPNs.&#xD;
&#xD;
        -  To assess the cytotoxicity and biologic activity of oral JAK inhibitor INCB18424 upon&#xD;
           phosphosignaling and mutation burden in pediatric patients whose leukemias or MPNs have&#xD;
           known CRLF2 and/or JAK mutations.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive oral JAK inhibitor INCB18424 twice daily on days 1-28. Courses repeat every&#xD;
      28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with relapsed or refractory leukemia may receive intrathecal chemotherapy in course&#xD;
      2 and subsequent courses at the discretion of the treating physician.&#xD;
&#xD;
      Plasma, bone marrow, and blood samples may be collected at baseline, during course 1, and&#xD;
      before subsequent courses for pharmacokinetic analysis and correlative biology studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose and/or recommended phase II dose</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>30 days post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and biologic activity</measure>
    <time_frame>Day 1 and Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (Ruxolitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ruxolitinib phosphate</intervention_name>
    <arm_group_label>Treatment (Ruxolitinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Treatment (Ruxolitinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Treatment (Ruxolitinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of one of the following:&#xD;
&#xD;
               -  Relapsed or refractory extracranial solid tumor&#xD;
&#xD;
               -  Relapsed or refractory leukemia&#xD;
&#xD;
                    -  At least 25% blasts in the bone marrow (M3) with the exception of patients&#xD;
                       with acute myeloid leukemia (AML), who must have &gt; 20% blasts in the bone&#xD;
                       marrow&#xD;
&#xD;
               -  Relapsed or refractory myeloproliferative neoplasm (MPN)&#xD;
&#xD;
                    -  At original diagnosis or relapse&#xD;
&#xD;
                    -  Current diagnostic criteria for MPNs include polycythemia vera, essential&#xD;
                       thrombocythemia, juvenile myelomonocytic leukemia, myelofibrosis, and&#xD;
                       atypical chronic myeloid leukemia&#xD;
&#xD;
               -  Relapsed or refractory leukemia or MPN that have confirmed JAK mutations and/or&#xD;
                  positive TSLPR surface staining&#xD;
&#xD;
                    -  Testing for JAK mutations and/or confirmed positive flow cytometry surface&#xD;
                       staining for the thymic stromal lymphopoietin receptor (TSLPR; encoded by&#xD;
                       CRLF2); eligibility for part C will be contingent upon patients&#xD;
                       demonstrating overexpression of CRLF2 by flow cytometric methods measured at&#xD;
                       either JHU or U. Washington flow laboratories (therefore, pre-enrollment&#xD;
                       samples need to be sent to one of these laboratories after discussion with&#xD;
                       Dr. Loh) or if the patient has a CLIA lab documented alteration in JAK1 or&#xD;
                       JAK2, SH2B3, IL7RA, or another gene that would predict sensitivity to JAK&#xD;
                       inhibition.&#xD;
&#xD;
          -  Measurable or evaluable disease (for patients with solid tumors)&#xD;
&#xD;
          -  Current disease state is one for which there is no known curative therapy or therapy&#xD;
             proven to prolong survival with an acceptable quality of life&#xD;
&#xD;
          -  No known active CNS involvement (radiographic or cytologic)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 50-100% (for patients &gt; 16 years old) or Lansky PS&#xD;
             50-100% (for patients ≤ 16 years old)&#xD;
&#xD;
               -  Patients who are unable to walk because of paralysis, but who can actively sit up&#xD;
                  in a wheelchair, will be considered ambulatory for the purpose of assessing the&#xD;
                  performance status&#xD;
&#xD;
          -  Patients with solid tumors* must meet the following criteria:&#xD;
&#xD;
               -  Peripheral ANC ≥ 1,000/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3 (transfusion-independent, defined as &gt; 7 days since&#xD;
                  prior platelet transfusions)&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
                    -  Not refractory to to red cell or platelet transfusion&#xD;
&#xD;
               -  ALT ≤ 110 U/L NOTE: *Patients with solid tumors and known bone marrow metastatic&#xD;
                  disease are eligible for study, but not evaluable for hematologic toxicity. These&#xD;
                  patients must not be known to be refractory to RBC or platelet transfusions.&#xD;
&#xD;
          -  Patients with leukemia or MPNs must meet the following criteria:&#xD;
&#xD;
               -  Platelet count ≥ 20,000/mm^3 (may receive platelet infusions)&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
               -  ALT ≤ 225 U/L&#xD;
&#xD;
          -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on&#xD;
             age/gender as follows:&#xD;
&#xD;
               -  ≤ 0.6 mg/dL (for patients 1 to &lt; 2 years old)&#xD;
&#xD;
               -  ≤ 0.8 mg/dL (for patients 2 to &lt; 6 years old)&#xD;
&#xD;
               -  ≤ 1 mg/dL (for patients 6 to &lt; 10 years old)&#xD;
&#xD;
               -  ≤ 1.2 mg/dL (for patients 10 to &lt; 13 years old)&#xD;
&#xD;
               -  ≤ 1.4 mg/dL (for female patients ≥ 13 years old)&#xD;
&#xD;
               -  ≤ 1.5 mg/dL (for male patients 13 to &lt; 16 years old)&#xD;
&#xD;
               -  ≤ 1.7 mg/dL (for male patients ≥ 16 years old)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 times upper limit of normal for age&#xD;
&#xD;
          -  Serum albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to swallow crushed or whole tablets&#xD;
&#xD;
               -  Nasogastric or G tube administration is not allowed&#xD;
&#xD;
          -  Body surface area ≥ 0.65 m^2 (for patients at dose level -1, 1, and 2)&#xD;
&#xD;
          -  No uncontrolled infection, including patients with known active HIV or chronic&#xD;
             hepatitis&#xD;
&#xD;
          -  No patients who, in the opinion of the investigator, may not be able to comply with&#xD;
             the safety monitoring requirements of the study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Fully recovered from the acute toxic effects of all prior anticancer therapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior total-body irradiation (TBI), craniospinal radiotherapy,&#xD;
             or radiotherapy to ≥ 50% of the pelvis (for patients with solid tumors)&#xD;
&#xD;
          -  At least 3 months since prior TBI, craniospinal radiotherapy, or radiotherapy to ≥ 50%&#xD;
             of the pelvis (for patients with leukemia)&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation or rescue without TBI and no&#xD;
             evidence of active graft-vs-host disease&#xD;
&#xD;
          -  At least 6 weeks since other substantial bone marrow radiation&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosourea) (for&#xD;
             patients with solid tumors)&#xD;
&#xD;
          -  At least 2 weeks since prior cytoxic chemotherapy (for patients with leukemia or MPNs)&#xD;
&#xD;
               -  Hydroxyurea may be initiated and continued for up to 24 hours before the start of&#xD;
                  study treatment&#xD;
&#xD;
               -  Intrathecal cytarabine (Ara-C) is not myelosuppressive chemotherapy&#xD;
&#xD;
               -  Patients with leukemia are permitted to receive intrathecal chemotherapy,&#xD;
                  including methotrexate or cytarabine, only if this is given at the time of&#xD;
                  diagnostic lumbar puncture at least 24 hours prior to the start of INCB018424&#xD;
&#xD;
          -  At least 2 weeks since prior long-acting hematopoietic growth factor (e.g., Neulasta)&#xD;
             or 1 week for a short-acting growth factor&#xD;
&#xD;
               -  For agents that have known adverse events occurring beyond 1 week, this period&#xD;
                  must be extended beyond the time during which adverse events are known to occur&#xD;
                  (as discussed with the study chair)&#xD;
&#xD;
          -  At least 1 week since prior therapy with a biologic (antineoplastic) agent&#xD;
&#xD;
               -  For agents that have known adverse events occurring beyond 1 week, this period&#xD;
                  must be extended beyond the time during which adverse events are known to occur&#xD;
                  (as discussed with the study chair)&#xD;
&#xD;
          -  At least 3 half-lives of antibody since prior monoclonal antibody&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy, radiotherapy,&#xD;
             immunotherapy, or biologic therapy&#xD;
&#xD;
          -  No concurrent systemic steroids (i.e., prednisone &gt; 10 mg)&#xD;
&#xD;
          -  No concurrent aspirin &gt; 150 mg/day&#xD;
&#xD;
          -  No concurrent medications for myelofibrosis (e.g., hydroxyurea, interferon,&#xD;
             thalidomide, busulfan, lenalidomide, or anagrelide)&#xD;
&#xD;
          -  No concurrent cyclosporine, tacrolimus, or other agents to prevent graft-vs-host&#xD;
             disease after bone marrow transplant or organ rejection after transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mignon Loh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado Center for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley's Children Cancer Center at Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital at University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0286</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center at Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>October 22, 2014</last_update_submitted>
  <last_update_submitted_qc>October 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>acute myeloid leukemia/transient myeloproliferative disorder</keyword>
  <keyword>primary myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

